Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

We evaluated the roles of calpain cleavage-related mutations of the integrin β3 cytoplasmic tail in integrin αIIbβ3 bidirectional signaling using a trans-dominant inhibition model. Chimeric Tac-β3 proteins (i.e., Tac-β3, Tac-β3Δ741, Tac-β3Δ747, Tac-β3Δ754, Tac-β3Δ759, and Tac-β3ΔNITY) consisting of the extracellular and transmembrane domains of human IL-2 receptor (Tac) and the human integrin β3 cytoplasmic domain were stably expressed in the 123 CHO cells harboring human glycoprotein Ib-IX and wild-type integrin αIIbβ3. The different cells were assayed for stable adhesion and spreading on immobilized fibrinogen, and for binding soluble fibrinogen representing outside-in and inside-out signaling events, respectively. The chimeric protein Tac-β3 inhibited, and Tac-β3ΔNITY partially attenuated stable adhesion and spreading. Tac-β3, Tac-β3Δ759, Tac-β3ΔNITY, and Tac-β3Δ754, but not Tac-β3Δ747 or Tac-β3Δ741, impaired the soluble fibrinogen binding. Results indicated that the bidirectional signaling was significantly inhibited by Tac-β3 and Tac-β3ΔNITY, albeit to a much lesser extent. Moreover, only inside-out signaling was impaired in the 123/Tac-β3Δ759 and 123/Tac-β3Δ754 cells in contrast to an intact bidirectional signaling in the 123/Tac-β3Δ747 and 123/Tac-β3Δ741 cells. In conclusion, the calpain cleavage of integrin β3 resulted in the regulatory effects on signaling by interrupting its interaction with cytoplasmic proteins rather than altering its conformation, and may thus regulate platelet function.

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11684-016-0460-0DOI Listing

Publication Analysis

Top Keywords

integrin β3
16
β3 cytoplasmic
12
bidirectional signaling
12
cytoplasmic tail
8
trans-dominant inhibition
8
inhibition model
8
integrin αiibβ3
8
tac-β3Δ759 tac-β3Δnity
8
stable adhesion
8
adhesion spreading
8

Similar Publications

Article Synopsis
  • GVHD in the GI tract is a leading cause of death after stem cell transplant, with higher Ann Arbor scores indicating worse outcomes and treatment resistance.
  • A phase 2 study tested natalizumab, a drug that targets T-cells, combined with corticosteroids for patients with severe GVHD, showing that it was safe and well-tolerated.
  • The results revealed no significant benefits of adding natalizumab, as patients had similar recovery and survival rates compared to those who only received corticosteroids.
View Article and Find Full Text PDF